CrystalGenomics Promotes Global Partnering at 'Bio Europe 2020'

Meeting with 27 Global Pharmaceutical and Biotech Companies

[Asia Economy Reporter Oh Ju-yeon] CrystalGenomics announced on the 27th that it will participate in 'BIO-EUROPE 2020,' one of the world's largest bio events.

CrystalGenomics will participate in 'BIO-Europe,' held online from the 26th to the 29th of this month (local time), and confirmed one-on-one partnering meetings for technology licensing negotiations of its pancreatic cancer treatment candidate Ivaltinostat, osteoarthritis treatment new drug Aselex, and superbug eradication drug candidates with 27 major global pharmaceutical and bio companies including AbbVie and Johnson & Johnson.

At this conference, several multinational pharmaceutical companies showed interest and requested meetings regarding the Phase 2 clinical data of Ivaltinostat, a pancreatic cancer drug candidate from CrystalGenomics' main pipeline, as well as its future development direction and the status of additional indication developments such as liver cancer.

A CrystalGenomics official said, "At this BIO-Europe, we will especially introduce the technology and potential of Ivaltinostat to various global pharmaceutical companies," adding, "This will provide an opportunity for more in-depth discussions to expand our global network."

Meanwhile, BIO-Europe, celebrating its 26th year this year, is the largest pharmaceutical and bio event in Europe, with more than 3,000 pharmaceutical and bio industry professionals from 60 countries worldwide participating to showcase the latest bio research achievements and bio development technologies.